- Research article
- Open Access
Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding
© Banerjee et al; licensee BioMed Central Ltd. 2006
Received: 26 December 2005
Accepted: 15 June 2006
Published: 15 June 2006
The Erratum to this article has been published in BMC Pharmacology 2006 6:14
Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological activity has potential therapeutic value for many vascular related diseases. CGRP is a 37 amino acid neuropeptide that signals through a G protein-coupled receptor belonging to the secretin receptor family. Previous studies on the calcitonin-like receptor (CLR), which requires co-expression of the receptor-activity-modifying protein-1 (RAMP1) to function as a CGRP receptor, have shown an 18 amino acid N-terminus sequence important for binding CGRP. Moreover, several investigations have recognized the C-terminal amidated phenylalanine (F37) of CGRP as essential for docking to the mature receptor. Therefore, we hypothesize that hydrophobic amino acids within the previously characterized 18 amino acid CLR N-terminus domain are important binding contacts for the C-terminal phenylalaninamide of CGRP.
Two leucine residues within this previously characterized CLR N-terminus domain, when mutated to alanine and expressed on HEK293T cells stably transfected with RAMP1, demonstrated a significantly decreased binding affinity for CGRP compared to wild type receptor. Additional decreases in binding affinity for CGRP were not found when both leucine mutations were expressed in the same CLR construct. Decreased binding characteristic of these leucine mutant receptors was observed for all CGRP ligands tested that contained the necessary amidated phenylalanine at their C-terminus. However, there was no difference in the potency of CGRP to increase cAMP production by these leucine mutant receptors when compared to wild type CLR, consistent with the notion that the neuropeptide C-terminal F37 is important for docking but not activation of the receptor. This observation was conserved when modified CGRP ligands lacking the amidated F37 demonstrated similar potencies to generate cAMP at both wild type and mutant CLRs. Furthermore, these modified CGRP ligands displayed a significant but similar loss of binding for all leucine mutant and wild type CLR because the important receptor contact on the neuropeptide was missing in all experimental situations.
These results are consistent with previous structure-function investigations of the neuropeptide and are the first to propose specific CLR binding contacts for the amidated F37 of CGRP that are important for docking but not activation of the mature CGRP receptor.
Calcitonin gene-related peptide (CGRP) released from sensory fibers originating in the trigeminal ganglia  or the adventitial-medial border of arteries supplying the heart  causes a potent, efficacious and long-lasting dilation of cerebral and coronary vessels, respectively [3, 4]. Vasodilatation of cerebral arteries by CGRP released from trigeminal fibers is implicated in the pathogenesis of migraine headaches . Conversely, vasodilatation by CGRP released in the peripheral vasculature might be of considerable importance to patients suffering from hypertension and/or heart disease [6, 7]. For example, it has been demonstrated that CGRP is essential for myocardial protection, during reperfusion injury, either in ischemic preconditioning or in heat stress-induced cardioprotection . However, lack of small molecule non-peptide CGRP receptor agonists or antagonists limit the essential investigations that would assess the role of this neuropeptide in vascular related diseases.
Structure-function relationships of CGRP have been extensively studied and are highlighted in a review by Wimalawansa . Briefly, this 37 amino acid neuropeptide can be divided into two distinct domains based upon its binding and agonistic properties for the receptor. The first N-terminal residues (1–7) have been shown to be essential for receptor activation . Specifically, loss of the disulfide bridge connecting amino acids 2 and 7 negates all biological activity of the endogenous neuropeptide . However, deleting this portion of the CGRP molecule does not appear to be critical for receptor affinity . Conversely, the N-terminal truncated peptide, CGRP(8–37), is an effective CGRP receptor antagonist having a high affinity for the receptor but devoid of any biological activity in itself . More specifically, the amidated C-terminal phenylalanine at position 37 of CGRP has been shown to be necessary for receptor interaction since deletion of this peptide residue or loss of the C-terminal amine results in a significant deficiency of high affinity binding [14, 15]. This affinity loss of des-F37-CGRP for the native receptor when compared to the endogenous neuropeptide is not due to disruption of the ligand structure . Instead, it is postulated that the C-terminal phenylalaninamide of the ligand directly interacts with the mature CGRP receptor in order for this high affinity binding to occur. Moreover, conservative substitution of F37 for tyrosine, which adds only one hydroxyl group to the phenol ring, again causes a significant loss of binding affinity, supporting the idea that CGRP-F37 is essential for high affinity interaction with the mature receptor protein . In addition, an α-helical configuration incorporating residues 8–18 and β-sheet structures related to amino acids 18–21 and 32–35 are also thought to contribute to the high affinity receptor antagonist profile of CGRP(8–37) [18, 19]. However, there is no information in the literature regarding specific interactions of the receptor with these identified ligand domains, particularly the C-terminus phenylalaninamide of CGRP.
The receptor for CGRP is a heptahelical membrane protein that belongs to the group B family of G protein-coupled receptors (GPCR). This GPCR family is distinct from the well characterized group A rhodopsin family of GPCRs in the fact that group B members have long extracellular N-terminus domains and utilize moderately sized peptides as their endogenous agonists . The human clone for this receptor has been identified and named the calcitonin-like receptor (CLR) protein based on sequence identity to the calcitonin receptor . However, transient mammalian cell expression of the human CLR clone could not be achieved until identification of a single transmembrane protein family called receptor-activity-modifying proteins (RAMPs) that are essential for trafficking mature CLR proteins to the cell membrane surface . In this study, heterodimerization of CLR-RAMP1 on the membrane surface was shown to exhibit the pharmacological profile of an endogenously expressed CGRP receptor. Conversely, interaction of CLR with RAMP2 or 3 on the membrane surface demonstrated the pharmacological receptor profile for a related peptide, adrenomedullin (AM). Therefore, cell specific expression of distinctive RAMPs with the CLR imparts selective pharmacological receptor profiles for related peptide families.
Specific to the CLR, deletion of an 18 amino acid region of the receptor N-terminal domain resulted in a significant loss of 125I-CGRP binding when co-expressed in mammalian cells with RAMP1 . However, this CLR deletion mutant was able to generate cAMP in a concentration-dependent manner with increasing amounts of CGRP. For our investigation, we considered whether the essential C-terminus phenylalaninamide of CGRP was contributing to high affinity neuropeptide binding by directly interacting with hydrophobic amino acids found within this deleted CLR N-terminal domain. Therefore, we used site-directed mutagenesis techniques to change these hydrophobic CLR residues to alanine, then characterized the binding and signaling properties of these transiently expressed CLR mutants for the endogenous or modified neuropeptides, comparing the results to wild type receptor. In this study, we identify two specific leucine residues within this N-terminal domain of the CLR that significantly contribute to the high affinity binding of CGRP without appreciably affecting receptor function.
Competitive radioligand binding properties of CGRP and modified peptide ligands for wild type and mutant CLRs
Comparisons of Kd and Ki values to previously published equilibrium dissociation constants for endogenous and modified CGRP ligands (in nM).
Reported Wild Type
0.9 ± 0.2
1.4 ± 0.3
0.4H, 32L a
8.9 ± 3.1
10.8 ± 2.2
9.3 ± 2.8
227 ± 86
3000 ± 1400
4600 ± 1200
2000 ± 1000
To specifically test this hypothesis we used modified peptide ligands, which lacked the C-terminus phenylalanine in additional competitive radioligand binding experiments. There was a significant affinity loss of the C-terminal amidated ligand, CGRP(1–36), for the wild type CLR transiently expressed on HEK293T-RAMP1 membranes when compared to the Ki of CGRP for the same receptor (Table 1). However, there were no differences in CGRP(1–36) affinity values for L24A, L34A and L24A,L34A receptor mutants when compared to wild type CLR. To confirm these observations we utilized another truncated CGRP fragment, which was not amidated at the carboxyl terminus. Similar to results using CGRP(1–36), there was a significant loss of CGRP(1–19) affinity for the wild type CLR when compared to the endogenous neuropeptide at the same receptor (Table 1). Nevertheless, this CGRP(1–19) affinity for the wild type receptor was analogous to values calculated for all leucine CLR mutations. These results emphasized the importance of the C-terminal F37 as an important binding contact for the wild type CLR (12). In addition, the lack of CGRP(1–36) or CGRP(1–19) affinity value changes for mutant compared to wild type CLRs, suggests that N-terminus leucines at positions 24 and 34 on the receptor might be interacting with F37 of the endogenous neuropeptide.
Signaling properties of stimulated wild type and mutant CLRs using CGRP or modified receptor active peptide ligands
Potency (EC50) values of endogenous and modified CGRP ligands to generate cAMP in transiently transfected HEK293T-RAMP1 cells (in nM).
1.6 ± 0.1
1.5 ± 0.4
2.0 ± 0.5
1.3 ± 0.2
4300 ± 800
3400 ± 700
5600 ± 800
4200 ± 1900
2100 ± 600
2400 ± 200
2200 ± 600
1600 ± 200
To support functional results observed for CGRP mediated generation of cAMP through wild type and CLR mutants, we used the truncated peptide, CGRP(1–36), which lacked F37 but was still amidated at the C-terminus. Increasing amounts of CGRP(1–36) was able to generate cAMP in HEK293T-RAMP1 cells transiently expressing the wild type CLR in a concentration-dependent manner (Fig 4B) The EC50 of CGRP(1–36) for the expressed wild type CLR-RAMP1 heterodimer was calculated to be 4.3 ± 0.8μM (n = 3). Although the CGRP(1–36) maximal response was similar, this EC50 was over 2,600-fold less than the value calculated for CGRP, indicating the importance of the peptide C-terminus F37 for receptor docking. Furthermore, increasing amounts of CGRP(1–36) were also used on HEK293T-RAMP1 cells transiently transfected with L24A, L34A or the L24A,L34A CLR double mutant (Fig 4B). Potency values of CGRP(1–36) to generated cAMP in these transfected cells were 3.4 ± 0.7μM (L24A), 5.6 ± 0.8μM (L34A) and 4.2 ± 1.9μM (L24A,L34A), respectively (n = 3). These CGRP(1–36) EC50 values for leucine CLR mutants were no different when compared to the potency of this modified ligand for increasing cAMP through the wild type receptor. Moreover, preincubation with 1μM of the CGRP receptor antagonist, CGRP(8–37), abolished the activity of 10μM CGRP(1–36) to generate cAMP through the wild type and leucine CLR mutants, indicating that this response was receptor specific (Fig 4B).
To substantiate results using CGRP(1–36), we characterized another truncated CGRP receptor active peptide, CGRP(1–19), which still lacked a C-terminal phenylalanine. Increasing amounts of CGRP(1–19) were able to generate increasing amounts of cAMP in HEK293T-RAMP1 cells transiently expressing the wild type CLR in a concentration-dependent manner (Fig 4C). The EC50 of CGRP(1–19) for the expressed wild type CGRP receptor was calculated to be 2.1 ± 0.6μM (n = 3). This EC50 value was similar to the potency of CGRP(1–36), but was considerably less than the calculated value of CGRP for the wild type receptor. This potency loss substantiates previous findings that illustrate the importance of this C-terminal CGRP-F37 for receptor docking. Furthermore, the maximal response initiated by CGRP(1–19) was appreciably less when compared to amounts of cAMP generated by activating the wild type receptor using CGRP(1–36) or the endogenous neuropeptide. This finding points to the contribution of peptide residues linking the C-terminal operative domains of CGRP for receptor agonism. Similarly, increasing amounts of CGRP(1–19) were also used on HEK293T-RAMP1 cells transiently transfected with L24A, L34A or the L24A,L34A CLR double mutant (Fig 4C). Potency values of CGRP(1–19) to generated cAMP in these transfected cells were 2.4 ± 0.2μM (L24A), 2.2 ± 0.6μM (L34A) and 1.6 ± 0.2μM (L24A,L34A), respectively (n = 3). EC50 values of CGRP(1–19) for these leucine mutants are no different when compared to the potency of this modified ligand to increase cAMP through the expressed wild type receptor. The consistent loss of potency for CGRP receptor active ligands lacking a C-terminal phenylalanine compared to the endogenous peptide support previous findings that highlight the importance of CGRP-F37 for docking but not activating the mature receptor and suggests that CRL residues L24 and L34 maybe required for this ligand-receptor interaction.
In this study we hypothesized that specific hydrophobic amino acids from a previously characterized N-terminal CLR deletion mutation  are important binding contacts for the C-terminus phenylalaninamide of the endogenous neuropeptide. This premise is based upon earlier structure-function investigations that divided CGRP into two distinct domains based upon its binding and agonistic properties for the endogenous receptor . Initial screening of all hydrophobic residues in this N-terminal domain of the CLR revealed that two leucine residues (L24 and L34), when mutated to alanine, demonstrated a significant binding affinity loss of [125I-Tyr]CGRP(8–37), CGRP or AcCGRP(19–37) for these specific CLR mutants when compared to the wild type receptor (Table 1). Differences in the magnitude of binding loss between CGRP and AcCGRP(19–37) for the wild type versus mutant CLRs can be attributed to the interaction of CGRP residues 8–18, which have been shown to also contribute towards the high affinity binding value of the ligand-receptor interaction [18, 30]. Moreover, there were no additional changes in the binding deficiency for [125I-Tyr]CGRP(8–37), CGRP and AcCGRP(19–37) when both leucine mutations were expressed in the same receptor protein, indicating that there is a cooperative but not synergistic relationship between these CLR residues for binding CGRP-F37 ligands. Additionally, the C-terminal phenylalaninamide is a shared residue between [125I-Tyr]CGRP(8–37), CGRP and AcCGRP(19–37). Therefore, compared to wild type CLR, binding affinity losses of these peptide ligands for the leucine CLR mutations suggests that L24 and L34 are significant binding contacts with CGRP-F37.
To support this hypothesis, we examined the binding properties of truncated CGRP ligands lacking the C-terminal phenylalanine for the wild type and leucine CLR mutations. There was a significant binding affinity loss of CGRP(1–36) or CGRP(1–19) when compared to the endogenous neuropeptide for the wild type CLR. These differences were not just due to modifications of functional groups at the carboxyl end because CGRP(1–36) was synthesized with an amidated C-terminus. Furthermore, this dissimilarity between CGRP(1–36) and CGRP was not due to configuration variations because previous biophysical measurements using circular dichroism spectroscopy and nuclear magnetic resonance have demonstrated no significant differences in the secondary structure of these peptides . This deficiency in binding affinity can be directly related to loss of the C-terminal phenylalanine, as has been described by others . However, this affinity loss was no different from wild type receptor when CGRP(1–36) or CGRP(1–19) were used to compete for specific L24A, L34A or L24A,L34A mutant CLR binding sites on transiently transfected HEK293T-RAMP1 cells. No changes in the binding parameters of these truncated C-terminus CGRP ligands for mutant or wild type CLRs indicates that similar contacts for peptide docking are shared between these membrane proteins. This is contrasted with binding affinity differences of CGRP ligands having a C-terminal phenylalaninamide for leucine CLR mutations versus wild type receptor. The only variation between these two sets of experiments is the C-terminus phenylalanine found on the endogenous neuropeptide. This binding property difference of truncated C-terminus peptide ligands versus CGRP for leucine mutants and wild type receptor proteins, strongly advocates CLR L24 and L34 as important binding contacts for CGRP-F37. Moreover, this is the first description for identifiable binding contacts on the CLR that specifically interacts with this essential neuropeptide phenylalaninamide.
We also assessed the functionality of these leucine CLR mutants to increase the CGRP mediated production of cAMP in an effort to understand the importance of these receptor residues for agonist-dependent activation. When compared to wild type receptor the potency of CGRP to increase cAMP production was no different for all three CLR leucine mutations (i.e., L24A, L34A and L24A,L34A; see Table 2). This is contrary to the 6- to 8-fold loss of CGRP binding affinity for these same CLR mutations. The ability of CGRP to activate both mutant and wild type receptors with similar potencies suggests there is some plasticity in the agonist binding pocket that can overcome variations in how the peptide docks with the receptor. As figure 1 illustrates, changes in docking the C-terminal portion of CGRP (i.e., F37) to these leucine CLR mutants, may alter presentation of the N-terminus CGRP domain to the agonist binding pocket of the mature receptor. However, no changes in the potency of CGRP for the CLR mutants versus wild type receptor indicates there is some flexibility of the CLR agonist binding pocket that can overcome modified docking arrangements of the neuropeptide. Moreover, this explanation for changes in CGRP binding affinity with no differences in potency for mutant versus wild type CLR supports the concept of two distinct neuropeptide domains responsible for receptor binding and agonism .
To validate this concept, we tested the ability of truncated C-terminal CGRP ligands to increase generation of cAMP in HEK293T-RAMP1 cells transiently expressing wild type and leucine CLR mutations. If these modified CGRP ligands still retain the essential agonist structures needed for receptor activation, then a concentration-dependent increase in the amount of cAMP generated should be observed even though a necessary amino acid for ligand-receptor docking is missing. For both CGRP(1–36) or CGRP(1–19) there was a concentration-dependent increase in the amount of cAMP produced from HEK293T-RAMP1 cells transiently expressing the wild type CLR (Table 2). However, the potency of these modified ligands was significantly less when compared to CGRP mediated production of cAMP from the same wild type receptor, which is directly related to loss of the phenylalaninamide. These results are similar to investigations where CGRP(1–36) was used for activating endogenous CGRP receptors on acutely isolated pancreatic acinar cells, to increase amylase release . Conversely, there was no significant potency differences of CGRP(1–36) or CGRP(1–19) for increasing cAMP in HEK293T-RAMP1 cells transiently expressing any of the leucine CLR mutations when compared to wild type receptor (Table 2). In addition, this increased cAMP production was specific for activating wild type or mutant CLRs because the response was blocked to basal levels using an effective concentration of the receptor antagonist, CGRP(8–37). The considerable binding affinity loss of truncated C-terminal CGRP ligands for wild type or mutant CLRs, while still being able to activate these same membrane proteins, validates the concept put forth in this study and by others for two distinct peptide ligand domains that manage docking and agonism of the endogenous neuropeptide .
Compared to wild type receptor, 8- to 20-fold differences in Ki values of these leucine CLR mutants for CGRP and AcCGRP(19–37) are not as extensive when contrasted to affinity changes of CGRP(1–36) and CGRP(1–19) for the wild type receptor (Table 1). Absence of these leucine CLR residues cannot explain the entire binding affinity loss of CGRP(1–36) for the wild type receptor. Consequently, it is reasonable to assume that interactions of CGRP-F37 with the mature CLR-RAMP1 heterodimer would necessitate a more complex relationship in order to account for the high affinity binding associated with the loss of this C-terminal peptide residue. For example, the non-peptide CGRP receptor antagonist, BIBN4096BS, has been shown to exhibit high affinity for the endogenous CGRP receptor expressed on SK-N-MC human neuroblastoma cells . In addition, this small molecule CGRP receptor antagonist can selectively be displaced in competition binding assays by CGRP and the receptor antagonist, CGRP(8–37) . Moreover, site-directed mutagenesis studies have documented the importance of a specific extracellular RAMP1 residue in determining BIBN4096BS antagonist affinity for the mature CGRP receptor complex . These observations not only indicate the specificity of BIBN4096BS for the mature CLR-RAMP1 heterodimer but suggest that important high-affinity binding contacts on the mature receptor complex maybe common between BIBN4096BS and CGRP. Therefore, it is plausible that the complex high-affinity receptor binding contacts for CGRP-F37 include not only leucine 24 and 34 on the N-terminal domain of the CLR, but also extracellular residues of RAMP1.
In summary, we have characterized specific leucine residues on the CLR membrane protein that participate in the high affinity CGRP binding mediated by the C-terminal phenylalaninamide of the neuropeptide. These CLR leucine residues do not directly participate in CGRP mediated receptor activation because they are not interacting with residues identified with the "agonist" domain of the peptide ligand. Alteration of either leucine CLR residue accounts for a significant loss of CGRP affinity. In addition, this CGRP affinity loss is no different when both leucines are modified in the same receptor protein, indicating that there is not a synergistic relationship between these CLR residues for CGRP binding. This paradigm for distinct binding and activation domains on CGRP for the mature receptor, as illustrated in figure 1, has also been shown using biophysical measurements of the binding mechanism for another group B GPCR . Although lacking the potential binding contributions of RAMP1, which are currently being investigated, this study is the first description of identifiable CLR residues important for docking CGRP to the receptor and will be useful in future studies that would build on our knowledge of this molecular relationship.
This study is the first to describe specific amino acids on the CLR N-terminus domain postulated to selectively interact with the C-terminal phenylalaninamide of CGRP, previously shown to impart the high affinity relationship of the neuropeptide with the mature CGRP receptor. This deduction is centered upon pharmacological properties of site-directed CLR mutations that are analogous to previous structure-function properties of the endogenous neuropeptide. Based on results from this study, a fundamental model of CGRP interaction with these N-terminus CLR leucine residues is brought forward. This molecular model serves as a starting point for future studies that examine the relationship of the CLR in forming a critical high affinity binding pocket with RAMP1 for CGRP. Our increased knowledge of the mature CGRP receptor binding pocket could lead to development of selective non-peptide small molecule ligands that would be useful in dissecting the important physiology of this abundant neuropeptide correlated with the pathological mechanisms for many vascular related diseases.
Wild type human CLR clone (GenBank:NM 005795) was a gift kindly provided by Steven M. Foord (GlaxoSmithKline Medicine Research Centre). Amidated CGRP(1–36) was custom synthesized by The Cleveland Clinic Foundation, Lerner Research Institute Core Peptide facility (Cleveland, OH). CGRP, CGRP(8–37), CGRP(1–19) and AcCGRP(19–37) was purchased from American Peptides (Sunnyvale, CA). Tyr0-CGRP(8–37) was a gift from Phoenix Pharmaceuticals (Belmont, CA). All peptides used for this study were amidated at the peptide C-terminus except CGRP(1–19). [125I-Tyr]CGRP(8–37) was synthesized by Robert C. Speth at the University of Mississippi Peptide Radioiodination Service Center (University, MS). Dulbecco's minimum essential medium (DMEM) and fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Atlanta, GA). HEK293T stably transfected with RAMP1 was a gift kindly provided by Michel Bouvier (University of Montreal, Quebec, Canada). cAMP Biotrak enzyme-linked immunoassay was purchased from Amersham Biosciences (Piscataway, NJ). Benzamidine, leupeptin, and phenylmethysulfonylfluoride was purchased from Sigma-Alrich (St Louis, MO). Whatman GF/C filter paper was purchased from Brandel (Gaithersburg, MD). All other acids, bases and salts were of the highest purity commercially available.
Site-directed mutagenesis was performed on a pcDNA3.1 human CLR construct utilizing QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufactures instructions. Transformed plasmid DNA from bacterial colonies that grew on selective media were isolated (Qiagen, Valencia, CA) and sequenced by the dideoxy method to verify the correct CLR mutation .
Mammalian cell culture
The parent and stably transfected HEK293 cell lines have previously been shown not to express endogenous calcitonin receptor or CLR proteins [22, 39, 40]. CLR negative HEK293T cells stably transfected with RAMP1 were propagated in DMEM plus 10% FBS under standard cell culture conditions. Confluent HEK293T-RAMP1 cells were washed in Hank's Balanced Salt Solution (HBSS), trypsinized and seeded at the appropriate density in 35 mm 6-well plates or P-150 dishes to ensure 50–80% cell confluence within 24 h. Transient transfection was performed after 24 h with GeneJammer transfection reagent according to the manufactures protocol (Stratagene, La Jolla, CA) using a 3μL reagent per 2μg plasmid DNA ratio for the transfection cocktail. Crude membrane preparations or cAMP signaling assays were performed on these HEK293T-RAMP1 cells 60–72 h post-transfection.
Crude membrane preparation
A crude cell membrane preparation was prepared as previously described . Briefly, HEK293T-RAMP1 membranes were prepared by scraping and transferring cells to a 50 mL conical tube using cold HBSS followed with two washings by centrifugation at 1000 × g using cold HBSS. The intact cell pellet was resuspended in 10 mL of 0.25 M sucrose containing a protease inhibitor cocktail consisting of 10μg/mL benzamidine, 10μg/mL leupeptin, and 20μg/mL phenylmethysulfonylfluoride. The cells were disrupted by freezing followed by Dounce homogenization of the thawed suspension using 20 strokes from a loose fitting (B) pestle. This mixture was then centrifuged at 1260 × g for 5 min at 4°C. Buffer A (20 mM HEPES, pH 7.5, 1.4 mM EGTA, 12.5 mM MgCl2, 10μg/mL benzamidine, 10μg/mL leupeptin, and 20μg/mL phenylmethysulfonylfluoride) was added to the supernatant and centrifuged again at 30,000 × g for 15 min at 4°C. The resultant pellet was kept, resuspended in buffer A then centrifuged once more at 30,000 × g for 15 min at 4°C. The final crude membrane pellet was resuspended in buffer A containing 10% glycerol and stored in aliquots at -70°C until used for radioligand binding. Protein concentrations were measured using the method of Bradford .
The radioligand binding protocol used for this study was performed as previously described . Briefly, the density of expressed CLR-RAMP1 heterodimers on HEK293T cells was determined by saturation binding experiments using the selective CGRP receptor antagonist [125I-Tyr]CGRP(8–37) as the radioligand. Crude HEK293T-RAMP1 cell membranes were allowed to equilibrate in siliconized polypropylene tubes at 37°C with increasing concentrations of [125I-Tyr]CGRP(8–37) in a 0.25 mL total volume of buffer A plus 0.1% BSA using 1μM CGRP to determine non-specific binding. Binding was stopped by filtering the membranes though Whatman GF/C glass fiber filters, followed by 5 – 5 mL washes with cold buffer B (20 mM HEPES, pH 7.5, 1.4 mM EGTA, 12.5 mM MgCl2) to remove any unbound drug. Amounts of total and non-specific radiolabel bound to cell membranes were calculated from radioactive counts remaining on the glass fiber filters. From the plotted saturation hyperbola, CGRP receptor density (Bmax) and the equilibrium dissociation constant (Kd) of [125I-Tyr]CGRP(8–37) for CLR-RAMP1 heterodimer binding sites were calculated using iterative non-linear regression analysis . Competition binding studies using increasing concentrations of unlabeled CGRP receptor active ligands were performed in the same buffer as the saturation binding experiments. Iterative non-linear regression analysis was again used to determine the concentration of unlabeled ligand that reduced specific [125I-Tyr]CGRP(8–37) binding by 50% (IC50). These IC50 values were used to calculate the equilibrium dissociation constants (Ki) of competing CGRP ligands for specific CLR-RAMP1 heterodimer binding sites expressed on HEK293T cells using the method of Cheng and Prusoff .
Quantitation of cAMP generation
60–72 h post-transfection, confluent HEK293T-RAMP1 cells were washed with HBSS then treated at 37°C in serum-free DMEM containing 1 mM 1-methyl-3-isobutylxanthine (IBMX) to inhibit phosphodiesterase in the presence or absence of 1μM CGRP(8–37). After 30 min, increasing concentrations of CGRP receptor agonists were added and the cells incubated for an additional 30 min at 37°C. At the end of this period, cells were lysed by 0.1M HCl and collected for determining the amount of cAMP generated using an enzyme-linked immunoassay according to the manufactures protocol (Amersham Biosciences, Piscataway, NJ). Briefly, 3H-cAMP added to cell lysates was used to compete with the endogenously produced cAMP for binding to a specific cAMP-binding protein. 3H-cAMP levels were then counted by liquid scintillation and related to endogenously generated cAMP by comparison with known standards. The concentration of CGRP receptor agonists that caused a half-maximal generation of cAMP (EC50) was calculated using nonlinear regression analysis (Graphpad, San Diego, CA).
The Biopolymer module in the Insight®II molecular modeling package (Accelyrs, San Diego, CA) was used to build models of CGRP residues 32–37 (NH2-VGSKAF-CONH2) and CLR residues 23–35 (NH2-ELEESPEDSIQLG-COOH). All charges were assigned for a pH value of 7. After building the CGRP C-terminal hexapeptide as an extended chain, backbone torsion angles of the peptide sequence were modified to match those from the original structure described by Breeze et al. . The CLR peptide was built as a helix then subjected to energy minimization with the Discover module of Insight®II using the Amber forcefield and a scalar dielectric constant of 78.54 (water at 25°C) . Energy minimization for the CLR peptide was achieved in two stages. The first stage of 500 steps was carried out using the steepest descents algorithm. The second stage was performed using the conjugate gradient algorithm with a convergence criterion of the derivative < 0.001, converging after 1390 iterations.
For each individual experiment, the fitted iterative nonlinear regression curve that best represented the data was determined using a partial f- test, F = [(SS1-SS2)/SS2]/[(DF1-DF2)/DF2], where SS = sum of the squares and DF = degrees of freedom (P < .05). From the best fit curve, EC50 and Ki values were calculated and compared between wild type and mutant CGRP receptors from concomitantly transfected HEK293T-RAMP1 cells. Significance between groups was tested using an unpaired two-tailed Student's t test (P < .05). All values are reported as the mean ± S.E. for n experiments, each performed in duplicate.
This work was supported in part by National Institutes of Health 5P20RR017699 from the COBRE program of the National Center for Research Resources. Computations were supported by National Institutes of Health P20RR016741 from the INBRE Program of the National Center for Research Resources, and the North Dakota Computational Chemistry and Biology Network (KAT). This work was also supported in part by the National Science Foundation 0235146 and the National Institutes of Health 1R15GM66726 and 5R21DK62865 (JEP).
- Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993, 33: 48-56. 10.1002/ana.410330109.View ArticlePubMedGoogle Scholar
- Gulbenkian S, Saetrum OO, Ekman R, Costa AN, Wharton J, Polak JM, Melo e Queiroz, Edvinsson L: Peptidergic innervation of human epicardial coronary arteries. Circ Res. 1993, 73: 579-588.View ArticlePubMedGoogle Scholar
- Edvinsson L, Sams A, Jansen-Olesen I, Tajti J, Kane SA, Rutledge RZ, Koblan KS, Hill RG, Longmore J: Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol. 2001, 415: 39-44. 10.1016/S0014-2999(00)00934-1.View ArticlePubMedGoogle Scholar
- Verheggen R, Wojtas K, Webel M, Hoffmann S, Kaumann AJ: BIBN4096BS and CGRP(8–37) antagonize the relaxant effects of alpha-CGRP more than those of beta-CGRP in human extracranial arteries. Naunyn Schmiedebergs Arch Pharmacol. 2005, 371: 383-392. 10.1007/s00210-005-1064-4.View ArticlePubMedGoogle Scholar
- Peroutka SJ: Neurogenic inflammation and migraine: Implications for the therapeutics. Mol Interv. 2005, 5: 304-311. 10.1124/mi.5.5.10.View ArticlePubMedGoogle Scholar
- Supowit SC, Rao A, Bowers MC, Zhao H, Fink G, Steficek B, Patel P, Katki KA, DiPette DJ: Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension. 2005, 45: 109-114.View ArticlePubMedGoogle Scholar
- Uren NG, Seydoux C, Davies GJ: Effect of intravenous calcitonin gene related peptide on ischaemia threshold and coronary stenosis severity in humans. Cardiovasc Res. 1993, 27: 1477-1481.View ArticlePubMedGoogle Scholar
- Li YJ, Peng J: The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. Eur J Pharmacol. 2002, 442: 173-177. 10.1016/S0014-2999(02)01538-8.View ArticlePubMedGoogle Scholar
- Wimalawansa SJ: Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996, 17: 533-585. 10.1210/er.17.5.533.View ArticlePubMedGoogle Scholar
- Maggi CA, Rovero P, Giuliani S, Evangelista S, Regoli D, Meli A: Biological activity of N-terminal fragments of calcitonin gene-related peptide. Eur J Pharmacol. 1990, 179: 217-219. 10.1016/0014-2999(90)90422-3.View ArticlePubMedGoogle Scholar
- Tippins JR, Di MV, Panico M, Morris HR, Macintyre I: Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochem Biophys Res Commun. 1986, 134: 1306-1311. 10.1016/0006-291X(86)90392-X.View ArticlePubMedGoogle Scholar
- Dennis T, Fournier A, St Pierre S, Quirion R: Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity. J Pharmacol Exp Ther. 1989, 251: 718-724.PubMedGoogle Scholar
- Chiba T, Yamaguchi A, Yamatani T, Nakamura A, Morishita T, Inui T, Fukase M, Noda T, Fujita T: Calcitonin gene-related peptide receptor antagonist human CGRP-(8–37). Am J Physiol. 1989, 256: E331-E335.PubMedGoogle Scholar
- Dumont Y, Fournier A, St Pierre S, Quirion R: A potent and selective CGRP2 agonist, [Cys(Et)2,7]hCGRP alpha : comparison in prototypical CGRP1 and CGRP2 in vitro bioassays. Can J Physiol Pharmacol. 1997, 75: 671-676. 10.1139/cjpp-75-6-671.View ArticlePubMedGoogle Scholar
- Poyner DR, Andrew DP, Brown D, Bose C, Hanley MR: Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes. Br J Pharmacol. 1992, 105: 441-447.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connell JP, Kelly SM, Raleigh DP, Hubbard JA, Price NC, Dobson CM, Smith BJ: On the role of the C-terminus of alpha-calcitonin-gene-related peptide (alpha CGRP). The structure of des-phenylalaninamide37-alpha CGRP and its interaction with the CGRP receptor. Biochem J. 1993, 291: 205-210.PubMed CentralView ArticlePubMedGoogle Scholar
- Rist B, Entzeroth M, Beck-Sickinger AG: From micromolar to nanomolar affinity: A systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. J Med Chem. 1998, 41: 117-123. 10.1021/jm970533r.View ArticlePubMedGoogle Scholar
- Howitt SG, Kilk K, Wang Y, Smith DM, Langel U, Poyner DR: The role of the 8–18 helix of CGRP8–37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. Br J Pharmacol. 2003, 138: 325-332. 10.1038/sj.bjp.0705040.PubMed CentralView ArticlePubMedGoogle Scholar
- Wisskirchen FM, Doyle PM, Gough SL, Harris CJ, Marshall I: Bioactive β-bend structures for the antagonist hα CGRP(8 – 37) at the CGRP1 receptor of the rat pulmonary artery. Br J Pharmacol. 2000, 129: 1049-1055. 10.1038/sj.bjp.0703152.PubMed CentralView ArticlePubMedGoogle Scholar
- Tams JW, Knudsen SM, Fahrenkrug J: Proposed arrangement of the seven transmembrane helices in the secretin receptor family. Receptors Channels. 1998, 5: 79-90.PubMedGoogle Scholar
- Fluhmann B, Muff R, Hunziker W, Fischer JA, Born W: A human orphan calcitonin receptor-like structure. Biochem Biophys Res Commun. 1995, 206: 341-347. 10.1006/bbrc.1995.1047.View ArticlePubMedGoogle Scholar
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998, 393: 333-339. 10.1038/30666.View ArticlePubMedGoogle Scholar
- Dong M, Pinon DI, Cox RF, Miller LJ: Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem. 2004, 279: 1167-1175. 10.1074/jbc.M305719200.View ArticlePubMedGoogle Scholar
- Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M: Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem. 2003, 278: 36531-36536. 10.1074/jbc.M304770200.View ArticlePubMedGoogle Scholar
- Chauhan M, Rajarathnam K, Yallampalli C: Role of the N-terminal domain of the calcitonin receptor-like receptor in ligand binding. Biochemistry. 2005, 44: 782-789. 10.1021/bi049153f.View ArticlePubMedGoogle Scholar
- Koller D, Born W, Leuthäuser K, McKinney RA, Fischer JA, Muff R: The extreme N-terminus of the calcitonin-like receptor contributes to the selective interaction with adrenomedullin or calcitonin gene-related peptide. FEBS Lett. 2002, 531: 464-468. 10.1016/S0014-5793(02)03585-8.View ArticlePubMedGoogle Scholar
- Van Rossum D, Menard DP, Fournier A, St Pierre S, Quirion R: Binding profile of a selective calcitonin gene-related peptide (CGRP) receptor antagonist ligand, [125I-Tyr]hCGRP8–37, in rat brain and peripheral tissues. J Pharmacol Exp Ther. 1994, 269: 846-853.PubMedGoogle Scholar
- Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of which causes 50 percent inhibition (I 50) of an enzymatic reaction. Biochem Pharmacol. 1973, 22: 3099-3108. 10.1016/0006-2952(73)90196-2.View ArticlePubMedGoogle Scholar
- Rovero P, Giuliani S, Maggi CA: CGRP antagonist activity of short C-terminal fragments of human alpha CGRP, CGRP(23–37) and CGRP(19–37). Peptides. 1992, 13: 1025-1027. 10.1016/0196-9781(92)90067-D.View ArticlePubMedGoogle Scholar
- Lynch B, Kaiser ET: Biological properties of two models of calcitonin gene related peptide with idealized amphiphilic α-helices of different lengths. Biochemistry. 1988, 27: 7600-7607. 10.1021/bi00420a005.View ArticlePubMedGoogle Scholar
- Poyner DR: Calcitonin gene-related peptide: Multiple actions, multiple receptors. Pharmacol Ther. 1992, 56: 32-51. 10.1016/0163-7258(92)90036-Y.View ArticleGoogle Scholar
- Smith DD, Li J, Wang Q, Murphy RF, Adrian TE, Elias Y, Bockman CS, Abel PW: Synthesis and biological activity of C-terminally truncated fragments of human α-calcitonin gene-related peptide. J Med Chem. 1993, 36: 2536-2541. 10.1021/jm00069a012.View ArticlePubMedGoogle Scholar
- Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000, 129: 420-423. 10.1038/sj.bjp.0703110.PubMed CentralView ArticlePubMedGoogle Scholar
- Schindler M, Doods HN: Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [3H]BIBN4096BS. Eur J Pharmacol. 2002, 442: 187-193. 10.1016/S0014-2999(02)01544-3.View ArticlePubMedGoogle Scholar
- Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, Kane SA: Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002, 277: 14294-14298. 10.1074/jbc.M109661200.View ArticlePubMedGoogle Scholar
- Ittner LM, Koller D, Muff R, Fischer JA, Born W: The N-terminal extracellular domain 23–60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry. 2005, 44: 5749-5754. 10.1021/bi048111o.View ArticlePubMedGoogle Scholar
- Castro M, Nikolaev VO, Palm D, Lohse MJ, Vilardaga JP: Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci USA. 2005, 102: 16084-16089. 10.1073/pnas.0503942102.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977, 74: 5463-5467. 10.1073/pnas.74.12.5463.PubMed CentralView ArticlePubMedGoogle Scholar
- Evdokiou A, Raggatt LJ, Atkins GJ, Findlay DM: Calcitonin receptor-mediated growth suppression of HEK-293 cells is accompanied by induction of p21WAF1/CIP1 and G2/M arrest. Mol Endocrinol. 1999, 13: 1738-1750. 10.1210/me.13.10.1738.View ArticlePubMedGoogle Scholar
- Hilairet S, Bélanger C, Bertrand J, Laperrié A, Foord SM, Bouvier M: Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and β-arrestin. J Biol Chem. 2001, 276: 42182-42190. 10.1074/jbc.M107323200.View ArticlePubMedGoogle Scholar
- Porter JE, Perez DM: Influence of a lysine 331 counterion on the pK a of aspartic acid 125: Evidence for a salt-bridge interaction and role in Alpha-1b adrenergic receptor activation. J Pharmacol Exp Ther. 2000, 292: 440-448.PubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.View ArticlePubMedGoogle Scholar
- Motulsky HJ, Ransnas LA: Fitting curves to data using nonlinear regression: A practical and nonmathmatical review. FASEB J. 1987, 1: 365-374.PubMedGoogle Scholar
- Breeze AL, Harvey TS, Bazzo R, Campbell ID: Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry. 1991, 30: 575-582. 10.1021/bi00216a036.View ArticlePubMedGoogle Scholar
- Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT: Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins. 1988, 4: 31-47. 10.1002/prot.340040106.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.